Skip to main content

Basic Science: Prejunctional and Presynaptic Trigeminovascular Targets: What Preclinical Evidence Is There?

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Inhibition of trigeminovascular nociceptive traffic by a prejunctional/presynaptic mechanism is an attractive approach for the treatment of migraine. It has been shown that blocking the presumed postsynaptic actions of calcitonin gene-related peptide (CGRP) is an effective acute antimigraine strategy, so that blockade of CGRP release by presynaptic inhibition also seems promising. A number of targets are reviewed including serotonin 5-HT1F and 5-HT1D receptor agonists, adenosine A1 receptor agonists, nociceptin, and vanilloid VR1 receptors. For each, the preclinical rationale for their involvement in prejunctional/presynaptic mechanisms is reviewed. Development of one or more such compounds offers the exciting prospect of new nonvasoconstrictor treatments for migraine and cluster headache.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1743-5013.2004.10103.x

Publication date: July 1, 2004

bsc/hec/2004/00000001/00000001/art00001
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more